Status:
UNKNOWN
Relationship Between Maternal Soluble Trigger Receptor Expressed on Myeloid Cells-1 (sTREM-1) and Placenta Accreta Spectrum
Lead Sponsor:
Necmettin Erbakan University
Conditions:
Placenta Accreta, Third Trimester
Eligibility:
FEMALE
Brief Summary
We planed to evaluate soluble the triggering receptors expressed on myeloid cell-1 (s TREM-1) levels in serum of pregnant women diagnosed with placenta accreta spectrum and compare it with healthy pre...
Detailed Description
Placenta accreta, which was a rare diagnosis before, is now one of the most important causes of postpartum hemorrhage and hysterectomy. Trigger receptor expressed on myeloid cells (TREM), interacts wi...
Eligibility Criteria
Inclusion
- placenta accreta spectrum diagnosis. 3rd trimester pregnancy, not having any additional disease, not in labor, not having multiple pregnancy.
Exclusion
- having multiple pregnancy, having any additional disease (preeclampsia, gestational diabetes mellitus, etc) , having an infection, being in labor.
- \-
Key Trial Info
Start Date :
November 14 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT05376410
Start Date
November 14 2021
End Date
July 1 2022
Last Update
May 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Necmettin Erbakan University Meram Medicine Faculty
Konya, Turkey (Türkiye)